author-photo

Jacob Korach

Sheba Medical Center
Tel Aviv University

118

Papers

2244

Citations

Citation Trend

Filter By

Papers (72) Sort By

Journal Conference Others

Risk-reducing salpingo-oophorectomy and breast cancer incidence among BRCA-mutation carriers.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers

2021 Fertility and Sterility
Show All
- Source
- Cite
- Save
Citations (1)
Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers—an Israeli matched-pair study

2021 International Journal of Gynecology & Obstetrics
Show All
- Source
- Cite
- Save
Citations (0)
Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
164 ENGOT-cx11/GOG 3047/KEYNOTE-A18: a phase 3, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer

2020 The Poster
Show All
- Source
- Cite
- Save
Citations (1)
Evaluation of an individualized starting dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study

2020
Show All
- Source
- Cite
- Save
Citations (2)
Abstract B06: Proteomic biomarker for detection of ovarian cancer using gynecologic liquid biopsy

2020
Show All
- Source
- Cite
- Save
Citations (0)
254TiP ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
405 Real-life response to standard of care in advanced ovarian cancer – an observational multi-national cohort study (RESPONSE)

2020
Show All
- Source
- Cite
- Save
Citations (0)
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (62)